CardiAMP Cell Therapy Heart Failure Trial Two Year Roll-In Cohort Data to be Presented at Heart Failure Society of America Annual Meeting
14 sept. 2022 07h00 HE
|
BioCardia, Inc.
Sunnyvale, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
CardiAMP Cell Therapy Heart Failure Trial to be Featured in Two Presentations at Heart Failure Society of America Annual Meeting 2021
10 sept. 2021 08h00 HE
|
BioCardia, Inc.
SAN CARLOS, Calif., Sept. 10, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a company focused on developing cellular and cell derived therapeutics for the treatment of cardiovascular and...